Antiviral susceptibility of influenza viruses isolated from patients pre- and post-administration of favipiravir.
Identifieur interne : 000522 ( PubMed/Curation ); précédent : 000521; suivant : 000523Antiviral susceptibility of influenza viruses isolated from patients pre- and post-administration of favipiravir.
Auteurs : Emi Takashita [Japon] ; Miho Ejima [Japon] ; Rie Ogawa [Japon] ; Seiichiro Fujisaki [Japon] ; Gabriele Neumann [États-Unis] ; Yousuke Furuta [Japon] ; Yoshihiro Kawaoka [Japon] ; Masato Tashiro [Japon] ; Takato Odagiri [Japon]Source :
- Antiviral research [ 1872-9096 ] ; 2016.
Descripteurs français
- KwdFr :
- Amides (pharmacologie), Amides (usage thérapeutique), Antiviraux (pharmacologie), Antiviraux (usage thérapeutique), Cellules cultivées, Effet cytopathogène viral (), Grippe humaine (traitement médicamenteux), Grippe humaine (virologie), Humains, Lignée cellulaire, Orthomyxoviridae (), Orthomyxoviridae (isolement et purification), Protéines virales (antagonistes et inhibiteurs), Pyrazines (pharmacologie), Pyrazines (usage thérapeutique), Relation dose-effet des médicaments, Résistance virale aux médicaments, Sialidase (antagonistes et inhibiteurs), Tests de sensibilité microbienne, Virus de la grippe A (), Virus de la grippe A (isolement et purification).
- MESH :
- antagonistes et inhibiteurs : Protéines virales, Sialidase.
- isolement et purification : Orthomyxoviridae, Virus de la grippe A.
- pharmacologie : Amides, Antiviraux, Pyrazines.
- traitement médicamenteux : Grippe humaine.
- usage thérapeutique : Amides, Antiviraux, Pyrazines.
- virologie : Grippe humaine.
- Cellules cultivées, Effet cytopathogène viral, Humains, Lignée cellulaire, Orthomyxoviridae, Relation dose-effet des médicaments, Résistance virale aux médicaments, Tests de sensibilité microbienne, Virus de la grippe A.
English descriptors
- KwdEn :
- Amides (pharmacology), Amides (therapeutic use), Antiviral Agents (pharmacology), Antiviral Agents (therapeutic use), Cell Line, Cells, Cultured, Cytopathogenic Effect, Viral (drug effects), Dose-Response Relationship, Drug, Drug Resistance, Viral, Humans, Influenza A virus (drug effects), Influenza A virus (isolation & purification), Influenza, Human (drug therapy), Influenza, Human (virology), Microbial Sensitivity Tests, Neuraminidase (antagonists & inhibitors), Orthomyxoviridae (drug effects), Orthomyxoviridae (isolation & purification), Pyrazines (pharmacology), Pyrazines (therapeutic use), Viral Proteins (antagonists & inhibitors).
- MESH :
- chemical , antagonists & inhibitors : Neuraminidase, Viral Proteins.
- chemical , pharmacology : Amides, Antiviral Agents, Pyrazines.
- chemical , therapeutic use : Amides, Antiviral Agents, Pyrazines.
- drug effects : Cytopathogenic Effect, Viral, Influenza A virus, Orthomyxoviridae.
- drug therapy : Influenza, Human.
- isolation & purification : Influenza A virus, Orthomyxoviridae.
- virology : Influenza, Human.
- Cell Line, Cells, Cultured, Dose-Response Relationship, Drug, Drug Resistance, Viral, Humans, Microbial Sensitivity Tests.
Abstract
Favipiravir, a viral RNA-dependent RNA polymerase inhibitor, has recently been approved in Japan for influenza pandemic preparedness. Here, we conducted a cell-based screening system to evaluate the susceptibility of influenza viruses to favipiravir. In this assay, the antiviral activity of favipiravir is determined by inhibition of virus-induced cytopathic effect, which can be measured by using a colorimetric cell proliferation assay. To demonstrate the robustness of the assay, we compared the favipiravir susceptibilities of neuraminidase (NA) inhibitor-resistant influenza A(H1N1)pdm09, A(H3N2), A(H7N9) and B viruses and their sensitive counterparts. No significant differences in the favipiravir susceptibilities were found between NA inhibitor-resistant and sensitive viruses. We, then, examined the antiviral susceptibility of 57 pairs of influenza viruses isolated from patients pre- and post-administration of favipiravir in phase 3 clinical trials. We found that there were no viruses with statistically significant reduced susceptibility to favipiravir or NA inhibitors, although two of 20 paired A(H1N1)pdm09, one of 17 paired A(H3N2) and one of 20 paired B viruses possessed amino acid substitutions in the RNA-dependent RNA polymerase subunits, PB1, PB2 and PA, after favipiravir administration. This is the first report on the antiviral susceptibility of influenza viruses isolated from patients after favipiravir treatment.
DOI: 10.1016/j.antiviral.2016.06.007
PubMed: 27321665
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: Pour aller vers cette notice dans l'étape Curation :000522
Links to Exploration step
pubmed:27321665Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Antiviral susceptibility of influenza viruses isolated from patients pre- and post-administration of favipiravir.</title><author><name sortKey="Takashita, Emi" sort="Takashita, Emi" uniqKey="Takashita E" first="Emi" last="Takashita">Emi Takashita</name><affiliation wicri:level="1"><nlm:affiliation>Influenza Virus Research Center, National Institute of Infectious Diseases, Gakuen 4-7-1, Musashimurayama, Tokyo, 208-0011, Japan.</nlm:affiliation><country xml:lang="fr">Japon</country><wicri:regionArea>Influenza Virus Research Center, National Institute of Infectious Diseases, Gakuen 4-7-1, Musashimurayama, Tokyo, 208-0011</wicri:regionArea></affiliation></author><author><name sortKey="Ejima, Miho" sort="Ejima, Miho" uniqKey="Ejima M" first="Miho" last="Ejima">Miho Ejima</name><affiliation wicri:level="1"><nlm:affiliation>Influenza Virus Research Center, National Institute of Infectious Diseases, Gakuen 4-7-1, Musashimurayama, Tokyo, 208-0011, Japan.</nlm:affiliation><country xml:lang="fr">Japon</country><wicri:regionArea>Influenza Virus Research Center, National Institute of Infectious Diseases, Gakuen 4-7-1, Musashimurayama, Tokyo, 208-0011</wicri:regionArea></affiliation></author><author><name sortKey="Ogawa, Rie" sort="Ogawa, Rie" uniqKey="Ogawa R" first="Rie" last="Ogawa">Rie Ogawa</name><affiliation wicri:level="1"><nlm:affiliation>Influenza Virus Research Center, National Institute of Infectious Diseases, Gakuen 4-7-1, Musashimurayama, Tokyo, 208-0011, Japan.</nlm:affiliation><country xml:lang="fr">Japon</country><wicri:regionArea>Influenza Virus Research Center, National Institute of Infectious Diseases, Gakuen 4-7-1, Musashimurayama, Tokyo, 208-0011</wicri:regionArea></affiliation></author><author><name sortKey="Fujisaki, Seiichiro" sort="Fujisaki, Seiichiro" uniqKey="Fujisaki S" first="Seiichiro" last="Fujisaki">Seiichiro Fujisaki</name><affiliation wicri:level="1"><nlm:affiliation>Influenza Virus Research Center, National Institute of Infectious Diseases, Gakuen 4-7-1, Musashimurayama, Tokyo, 208-0011, Japan.</nlm:affiliation><country xml:lang="fr">Japon</country><wicri:regionArea>Influenza Virus Research Center, National Institute of Infectious Diseases, Gakuen 4-7-1, Musashimurayama, Tokyo, 208-0011</wicri:regionArea></affiliation></author><author><name sortKey="Neumann, Gabriele" sort="Neumann, Gabriele" uniqKey="Neumann G" first="Gabriele" last="Neumann">Gabriele Neumann</name><affiliation wicri:level="1"><nlm:affiliation>Department of Pathobiological Sciences, School of Veterinary Medicine, University of Wisconsin-Madison, 575 Science Drive, Madison, WI 53711, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Pathobiological Sciences, School of Veterinary Medicine, University of Wisconsin-Madison, 575 Science Drive, Madison, WI 53711</wicri:regionArea></affiliation></author><author><name sortKey="Furuta, Yousuke" sort="Furuta, Yousuke" uniqKey="Furuta Y" first="Yousuke" last="Furuta">Yousuke Furuta</name><affiliation wicri:level="1"><nlm:affiliation>Toyama Chemical Co., Ltd., 4-1, Shimookui 2-chome, Toyama, 930-8508, Japan.</nlm:affiliation><country xml:lang="fr">Japon</country><wicri:regionArea>Toyama Chemical Co., Ltd., 4-1, Shimookui 2-chome, Toyama, 930-8508</wicri:regionArea></affiliation></author><author><name sortKey="Kawaoka, Yoshihiro" sort="Kawaoka, Yoshihiro" uniqKey="Kawaoka Y" first="Yoshihiro" last="Kawaoka">Yoshihiro Kawaoka</name><affiliation wicri:level="1"><nlm:affiliation>Department of Pathobiological Sciences, School of Veterinary Medicine, University of Wisconsin-Madison, 575 Science Drive, Madison, WI 53711, USA; Division of Virology, Department of Microbiology and Immunology, Institute of Medical Science, University of Tokyo, Tokyo, 108-8639, Japan; Department of Special Pathogens, International Research Center for Infectious Diseases, Institute of Medical Science, University of Tokyo, Minato-ku, Tokyo, 108-8639, Japan.</nlm:affiliation><country xml:lang="fr">Japon</country><wicri:regionArea>Department of Pathobiological Sciences, School of Veterinary Medicine, University of Wisconsin-Madison, 575 Science Drive, Madison, WI 53711, USA; Division of Virology, Department of Microbiology and Immunology, Institute of Medical Science, University of Tokyo, Tokyo, 108-8639, Japan; Department of Special Pathogens, International Research Center for Infectious Diseases, Institute of Medical Science, University of Tokyo, Minato-ku, Tokyo, 108-8639</wicri:regionArea></affiliation></author><author><name sortKey="Tashiro, Masato" sort="Tashiro, Masato" uniqKey="Tashiro M" first="Masato" last="Tashiro">Masato Tashiro</name><affiliation wicri:level="1"><nlm:affiliation>Influenza Virus Research Center, National Institute of Infectious Diseases, Gakuen 4-7-1, Musashimurayama, Tokyo, 208-0011, Japan.</nlm:affiliation><country xml:lang="fr">Japon</country><wicri:regionArea>Influenza Virus Research Center, National Institute of Infectious Diseases, Gakuen 4-7-1, Musashimurayama, Tokyo, 208-0011</wicri:regionArea></affiliation></author><author><name sortKey="Odagiri, Takato" sort="Odagiri, Takato" uniqKey="Odagiri T" first="Takato" last="Odagiri">Takato Odagiri</name><affiliation wicri:level="1"><nlm:affiliation>Influenza Virus Research Center, National Institute of Infectious Diseases, Gakuen 4-7-1, Musashimurayama, Tokyo, 208-0011, Japan. Electronic address: todagiri@nih.go.jp.</nlm:affiliation><country xml:lang="fr">Japon</country><wicri:regionArea>Influenza Virus Research Center, National Institute of Infectious Diseases, Gakuen 4-7-1, Musashimurayama, Tokyo, 208-0011</wicri:regionArea></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2016">2016</date><idno type="RBID">pubmed:27321665</idno><idno type="pmid">27321665</idno><idno type="doi">10.1016/j.antiviral.2016.06.007</idno><idno type="wicri:Area/PubMed/Corpus">000522</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000522</idno><idno type="wicri:Area/PubMed/Curation">000522</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000522</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Antiviral susceptibility of influenza viruses isolated from patients pre- and post-administration of favipiravir.</title><author><name sortKey="Takashita, Emi" sort="Takashita, Emi" uniqKey="Takashita E" first="Emi" last="Takashita">Emi Takashita</name><affiliation wicri:level="1"><nlm:affiliation>Influenza Virus Research Center, National Institute of Infectious Diseases, Gakuen 4-7-1, Musashimurayama, Tokyo, 208-0011, Japan.</nlm:affiliation><country xml:lang="fr">Japon</country><wicri:regionArea>Influenza Virus Research Center, National Institute of Infectious Diseases, Gakuen 4-7-1, Musashimurayama, Tokyo, 208-0011</wicri:regionArea></affiliation></author><author><name sortKey="Ejima, Miho" sort="Ejima, Miho" uniqKey="Ejima M" first="Miho" last="Ejima">Miho Ejima</name><affiliation wicri:level="1"><nlm:affiliation>Influenza Virus Research Center, National Institute of Infectious Diseases, Gakuen 4-7-1, Musashimurayama, Tokyo, 208-0011, Japan.</nlm:affiliation><country xml:lang="fr">Japon</country><wicri:regionArea>Influenza Virus Research Center, National Institute of Infectious Diseases, Gakuen 4-7-1, Musashimurayama, Tokyo, 208-0011</wicri:regionArea></affiliation></author><author><name sortKey="Ogawa, Rie" sort="Ogawa, Rie" uniqKey="Ogawa R" first="Rie" last="Ogawa">Rie Ogawa</name><affiliation wicri:level="1"><nlm:affiliation>Influenza Virus Research Center, National Institute of Infectious Diseases, Gakuen 4-7-1, Musashimurayama, Tokyo, 208-0011, Japan.</nlm:affiliation><country xml:lang="fr">Japon</country><wicri:regionArea>Influenza Virus Research Center, National Institute of Infectious Diseases, Gakuen 4-7-1, Musashimurayama, Tokyo, 208-0011</wicri:regionArea></affiliation></author><author><name sortKey="Fujisaki, Seiichiro" sort="Fujisaki, Seiichiro" uniqKey="Fujisaki S" first="Seiichiro" last="Fujisaki">Seiichiro Fujisaki</name><affiliation wicri:level="1"><nlm:affiliation>Influenza Virus Research Center, National Institute of Infectious Diseases, Gakuen 4-7-1, Musashimurayama, Tokyo, 208-0011, Japan.</nlm:affiliation><country xml:lang="fr">Japon</country><wicri:regionArea>Influenza Virus Research Center, National Institute of Infectious Diseases, Gakuen 4-7-1, Musashimurayama, Tokyo, 208-0011</wicri:regionArea></affiliation></author><author><name sortKey="Neumann, Gabriele" sort="Neumann, Gabriele" uniqKey="Neumann G" first="Gabriele" last="Neumann">Gabriele Neumann</name><affiliation wicri:level="1"><nlm:affiliation>Department of Pathobiological Sciences, School of Veterinary Medicine, University of Wisconsin-Madison, 575 Science Drive, Madison, WI 53711, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Pathobiological Sciences, School of Veterinary Medicine, University of Wisconsin-Madison, 575 Science Drive, Madison, WI 53711</wicri:regionArea></affiliation></author><author><name sortKey="Furuta, Yousuke" sort="Furuta, Yousuke" uniqKey="Furuta Y" first="Yousuke" last="Furuta">Yousuke Furuta</name><affiliation wicri:level="1"><nlm:affiliation>Toyama Chemical Co., Ltd., 4-1, Shimookui 2-chome, Toyama, 930-8508, Japan.</nlm:affiliation><country xml:lang="fr">Japon</country><wicri:regionArea>Toyama Chemical Co., Ltd., 4-1, Shimookui 2-chome, Toyama, 930-8508</wicri:regionArea></affiliation></author><author><name sortKey="Kawaoka, Yoshihiro" sort="Kawaoka, Yoshihiro" uniqKey="Kawaoka Y" first="Yoshihiro" last="Kawaoka">Yoshihiro Kawaoka</name><affiliation wicri:level="1"><nlm:affiliation>Department of Pathobiological Sciences, School of Veterinary Medicine, University of Wisconsin-Madison, 575 Science Drive, Madison, WI 53711, USA; Division of Virology, Department of Microbiology and Immunology, Institute of Medical Science, University of Tokyo, Tokyo, 108-8639, Japan; Department of Special Pathogens, International Research Center for Infectious Diseases, Institute of Medical Science, University of Tokyo, Minato-ku, Tokyo, 108-8639, Japan.</nlm:affiliation><country xml:lang="fr">Japon</country><wicri:regionArea>Department of Pathobiological Sciences, School of Veterinary Medicine, University of Wisconsin-Madison, 575 Science Drive, Madison, WI 53711, USA; Division of Virology, Department of Microbiology and Immunology, Institute of Medical Science, University of Tokyo, Tokyo, 108-8639, Japan; Department of Special Pathogens, International Research Center for Infectious Diseases, Institute of Medical Science, University of Tokyo, Minato-ku, Tokyo, 108-8639</wicri:regionArea></affiliation></author><author><name sortKey="Tashiro, Masato" sort="Tashiro, Masato" uniqKey="Tashiro M" first="Masato" last="Tashiro">Masato Tashiro</name><affiliation wicri:level="1"><nlm:affiliation>Influenza Virus Research Center, National Institute of Infectious Diseases, Gakuen 4-7-1, Musashimurayama, Tokyo, 208-0011, Japan.</nlm:affiliation><country xml:lang="fr">Japon</country><wicri:regionArea>Influenza Virus Research Center, National Institute of Infectious Diseases, Gakuen 4-7-1, Musashimurayama, Tokyo, 208-0011</wicri:regionArea></affiliation></author><author><name sortKey="Odagiri, Takato" sort="Odagiri, Takato" uniqKey="Odagiri T" first="Takato" last="Odagiri">Takato Odagiri</name><affiliation wicri:level="1"><nlm:affiliation>Influenza Virus Research Center, National Institute of Infectious Diseases, Gakuen 4-7-1, Musashimurayama, Tokyo, 208-0011, Japan. Electronic address: todagiri@nih.go.jp.</nlm:affiliation><country xml:lang="fr">Japon</country><wicri:regionArea>Influenza Virus Research Center, National Institute of Infectious Diseases, Gakuen 4-7-1, Musashimurayama, Tokyo, 208-0011</wicri:regionArea></affiliation></author></analytic><series><title level="j">Antiviral research</title><idno type="eISSN">1872-9096</idno><imprint><date when="2016" type="published">2016</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Amides (pharmacology)</term><term>Amides (therapeutic use)</term><term>Antiviral Agents (pharmacology)</term><term>Antiviral Agents (therapeutic use)</term><term>Cell Line</term><term>Cells, Cultured</term><term>Cytopathogenic Effect, Viral (drug effects)</term><term>Dose-Response Relationship, Drug</term><term>Drug Resistance, Viral</term><term>Humans</term><term>Influenza A virus (drug effects)</term><term>Influenza A virus (isolation & purification)</term><term>Influenza, Human (drug therapy)</term><term>Influenza, Human (virology)</term><term>Microbial Sensitivity Tests</term><term>Neuraminidase (antagonists & inhibitors)</term><term>Orthomyxoviridae (drug effects)</term><term>Orthomyxoviridae (isolation & purification)</term><term>Pyrazines (pharmacology)</term><term>Pyrazines (therapeutic use)</term><term>Viral Proteins (antagonists & inhibitors)</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Amides (pharmacologie)</term><term>Amides (usage thérapeutique)</term><term>Antiviraux (pharmacologie)</term><term>Antiviraux (usage thérapeutique)</term><term>Cellules cultivées</term><term>Effet cytopathogène viral ()</term><term>Grippe humaine (traitement médicamenteux)</term><term>Grippe humaine (virologie)</term><term>Humains</term><term>Lignée cellulaire</term><term>Orthomyxoviridae ()</term><term>Orthomyxoviridae (isolement et purification)</term><term>Protéines virales (antagonistes et inhibiteurs)</term><term>Pyrazines (pharmacologie)</term><term>Pyrazines (usage thérapeutique)</term><term>Relation dose-effet des médicaments</term><term>Résistance virale aux médicaments</term><term>Sialidase (antagonistes et inhibiteurs)</term><term>Tests de sensibilité microbienne</term><term>Virus de la grippe A ()</term><term>Virus de la grippe A (isolement et purification)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="antagonists & inhibitors" xml:lang="en"><term>Neuraminidase</term><term>Viral Proteins</term></keywords><keywords scheme="MESH" type="chemical" qualifier="pharmacology" xml:lang="en"><term>Amides</term><term>Antiviral Agents</term><term>Pyrazines</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Amides</term><term>Antiviral Agents</term><term>Pyrazines</term></keywords><keywords scheme="MESH" qualifier="antagonistes et inhibiteurs" xml:lang="fr"><term>Protéines virales</term><term>Sialidase</term></keywords><keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Cytopathogenic Effect, Viral</term><term>Influenza A virus</term><term>Orthomyxoviridae</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Influenza, Human</term></keywords><keywords scheme="MESH" qualifier="isolation & purification" xml:lang="en"><term>Influenza A virus</term><term>Orthomyxoviridae</term></keywords><keywords scheme="MESH" qualifier="isolement et purification" xml:lang="fr"><term>Orthomyxoviridae</term><term>Virus de la grippe A</term></keywords><keywords scheme="MESH" qualifier="pharmacologie" xml:lang="fr"><term>Amides</term><term>Antiviraux</term><term>Pyrazines</term></keywords><keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Grippe humaine</term></keywords><keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>Amides</term><term>Antiviraux</term><term>Pyrazines</term></keywords><keywords scheme="MESH" qualifier="virologie" xml:lang="fr"><term>Grippe humaine</term></keywords><keywords scheme="MESH" qualifier="virology" xml:lang="en"><term>Influenza, Human</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Cell Line</term><term>Cells, Cultured</term><term>Dose-Response Relationship, Drug</term><term>Drug Resistance, Viral</term><term>Humans</term><term>Microbial Sensitivity Tests</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Cellules cultivées</term><term>Effet cytopathogène viral</term><term>Humains</term><term>Lignée cellulaire</term><term>Orthomyxoviridae</term><term>Relation dose-effet des médicaments</term><term>Résistance virale aux médicaments</term><term>Tests de sensibilité microbienne</term><term>Virus de la grippe A</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Favipiravir, a viral RNA-dependent RNA polymerase inhibitor, has recently been approved in Japan for influenza pandemic preparedness. Here, we conducted a cell-based screening system to evaluate the susceptibility of influenza viruses to favipiravir. In this assay, the antiviral activity of favipiravir is determined by inhibition of virus-induced cytopathic effect, which can be measured by using a colorimetric cell proliferation assay. To demonstrate the robustness of the assay, we compared the favipiravir susceptibilities of neuraminidase (NA) inhibitor-resistant influenza A(H1N1)pdm09, A(H3N2), A(H7N9) and B viruses and their sensitive counterparts. No significant differences in the favipiravir susceptibilities were found between NA inhibitor-resistant and sensitive viruses. We, then, examined the antiviral susceptibility of 57 pairs of influenza viruses isolated from patients pre- and post-administration of favipiravir in phase 3 clinical trials. We found that there were no viruses with statistically significant reduced susceptibility to favipiravir or NA inhibitors, although two of 20 paired A(H1N1)pdm09, one of 17 paired A(H3N2) and one of 20 paired B viruses possessed amino acid substitutions in the RNA-dependent RNA polymerase subunits, PB1, PB2 and PA, after favipiravir administration. This is the first report on the antiviral susceptibility of influenza viruses isolated from patients after favipiravir treatment.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">27321665</PMID><DateCompleted><Year>2017</Year><Month>11</Month><Day>16</Day></DateCompleted><DateRevised><Year>2018</Year><Month>03</Month><Day>09</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1872-9096</ISSN><JournalIssue CitedMedium="Internet"><Volume>132</Volume><PubDate><Year>2016</Year><Month>08</Month></PubDate></JournalIssue><Title>Antiviral research</Title><ISOAbbreviation>Antiviral Res.</ISOAbbreviation></Journal><ArticleTitle>Antiviral susceptibility of influenza viruses isolated from patients pre- and post-administration of favipiravir.</ArticleTitle><Pagination><MedlinePgn>170-7</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.antiviral.2016.06.007</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0166-3542(16)30338-2</ELocationID><Abstract><AbstractText>Favipiravir, a viral RNA-dependent RNA polymerase inhibitor, has recently been approved in Japan for influenza pandemic preparedness. Here, we conducted a cell-based screening system to evaluate the susceptibility of influenza viruses to favipiravir. In this assay, the antiviral activity of favipiravir is determined by inhibition of virus-induced cytopathic effect, which can be measured by using a colorimetric cell proliferation assay. To demonstrate the robustness of the assay, we compared the favipiravir susceptibilities of neuraminidase (NA) inhibitor-resistant influenza A(H1N1)pdm09, A(H3N2), A(H7N9) and B viruses and their sensitive counterparts. No significant differences in the favipiravir susceptibilities were found between NA inhibitor-resistant and sensitive viruses. We, then, examined the antiviral susceptibility of 57 pairs of influenza viruses isolated from patients pre- and post-administration of favipiravir in phase 3 clinical trials. We found that there were no viruses with statistically significant reduced susceptibility to favipiravir or NA inhibitors, although two of 20 paired A(H1N1)pdm09, one of 17 paired A(H3N2) and one of 20 paired B viruses possessed amino acid substitutions in the RNA-dependent RNA polymerase subunits, PB1, PB2 and PA, after favipiravir administration. This is the first report on the antiviral susceptibility of influenza viruses isolated from patients after favipiravir treatment.</AbstractText><CopyrightInformation>Copyright © 2016 The Authors. Published by Elsevier B.V. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Takashita</LastName><ForeName>Emi</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Influenza Virus Research Center, National Institute of Infectious Diseases, Gakuen 4-7-1, Musashimurayama, Tokyo, 208-0011, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ejima</LastName><ForeName>Miho</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Influenza Virus Research Center, National Institute of Infectious Diseases, Gakuen 4-7-1, Musashimurayama, Tokyo, 208-0011, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ogawa</LastName><ForeName>Rie</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Influenza Virus Research Center, National Institute of Infectious Diseases, Gakuen 4-7-1, Musashimurayama, Tokyo, 208-0011, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fujisaki</LastName><ForeName>Seiichiro</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Influenza Virus Research Center, National Institute of Infectious Diseases, Gakuen 4-7-1, Musashimurayama, Tokyo, 208-0011, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Neumann</LastName><ForeName>Gabriele</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Pathobiological Sciences, School of Veterinary Medicine, University of Wisconsin-Madison, 575 Science Drive, Madison, WI 53711, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Furuta</LastName><ForeName>Yousuke</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Toyama Chemical Co., Ltd., 4-1, Shimookui 2-chome, Toyama, 930-8508, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kawaoka</LastName><ForeName>Yoshihiro</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Pathobiological Sciences, School of Veterinary Medicine, University of Wisconsin-Madison, 575 Science Drive, Madison, WI 53711, USA; Division of Virology, Department of Microbiology and Immunology, Institute of Medical Science, University of Tokyo, Tokyo, 108-8639, Japan; Department of Special Pathogens, International Research Center for Infectious Diseases, Institute of Medical Science, University of Tokyo, Minato-ku, Tokyo, 108-8639, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tashiro</LastName><ForeName>Masato</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Influenza Virus Research Center, National Institute of Infectious Diseases, Gakuen 4-7-1, Musashimurayama, Tokyo, 208-0011, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Odagiri</LastName><ForeName>Takato</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Influenza Virus Research Center, National Institute of Infectious Diseases, Gakuen 4-7-1, Musashimurayama, Tokyo, 208-0011, Japan. Electronic address: todagiri@nih.go.jp.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>HHSN266200700010C</GrantID><Acronym>AI</Acronym><Agency>NIAID NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2016</Year><Month>06</Month><Day>16</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>Antiviral Res</MedlineTA><NlmUniqueID>8109699</NlmUniqueID><ISSNLinking>0166-3542</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000577">Amides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000998">Antiviral Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011719">Pyrazines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014764">Viral Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.2.1.18</RegistryNumber><NameOfSubstance UI="C487630">NA protein, influenza A virus</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.2.1.18</RegistryNumber><NameOfSubstance UI="D009439">Neuraminidase</NameOfSubstance></Chemical><Chemical><RegistryNumber>EW5GL2X7E0</RegistryNumber><NameOfSubstance UI="C462182">favipiravir</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000577" MajorTopicYN="N">Amides</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000998" MajorTopicYN="N">Antiviral Agents</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002460" MajorTopicYN="N">Cell Line</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002478" MajorTopicYN="N">Cells, Cultured</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003588" MajorTopicYN="N">Cytopathogenic Effect, Viral</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004305" MajorTopicYN="N">Dose-Response Relationship, Drug</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D024882" MajorTopicYN="N">Drug Resistance, Viral</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009980" MajorTopicYN="N">Influenza A virus</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000302" MajorTopicYN="N">isolation & purification</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007251" MajorTopicYN="N">Influenza, Human</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000821" MajorTopicYN="Y">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008826" MajorTopicYN="N">Microbial Sensitivity Tests</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009439" MajorTopicYN="N">Neuraminidase</DescriptorName><QualifierName UI="Q000037" MajorTopicYN="N">antagonists & inhibitors</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009975" MajorTopicYN="N">Orthomyxoviridae</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName><QualifierName UI="Q000302" MajorTopicYN="N">isolation & purification</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011719" MajorTopicYN="N">Pyrazines</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014764" MajorTopicYN="N">Viral Proteins</DescriptorName><QualifierName UI="Q000037" MajorTopicYN="N">antagonists & inhibitors</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="Y">Antiviral resistance</Keyword><Keyword MajorTopicYN="Y">Favipiravir</Keyword><Keyword MajorTopicYN="Y">Influenza</Keyword><Keyword MajorTopicYN="Y">Polymerase inhibitor</Keyword><Keyword MajorTopicYN="Y">T-705</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2015</Year><Month>08</Month><Day>05</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2016</Year><Month>06</Month><Day>09</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2016</Year><Month>06</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2016</Year><Month>6</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2016</Year><Month>6</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2017</Year><Month>11</Month><Day>29</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">27321665</ArticleId><ArticleId IdType="pii">S0166-3542(16)30338-2</ArticleId><ArticleId IdType="doi">10.1016/j.antiviral.2016.06.007</ArticleId></ArticleIdList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/PandemieGrippaleV1/Data/PubMed/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000522 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd -nk 000522 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= PandemieGrippaleV1
|flux= PubMed
|étape= Curation
|type= RBID
|clé= pubmed:27321665
|texte= Antiviral susceptibility of influenza viruses isolated from patients pre- and post-administration of favipiravir.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Curation/RBID.i -Sk "pubmed:27321665" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd \
| NlmPubMed2Wicri -a PandemieGrippaleV1
| This area was generated with Dilib version V0.6.34. |  |